Urology · Pontiac, MI
NPI
1871558569
Since 2006
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
44200 Woodward, Suite 207
Pontiac, MI, 48341
Phone (248) 322-6103
Groups this clinician bills Medicare through
Medicare paid, 2024
$422K
13,101 services
Medicare patients, 2024
1,128
Average age 76
Drug cost, 2024
$860K
6,032 prescriptions
Company payments, 2025
$1,014
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marko R Gudziak was code 81003 (clinical chemistry), 1,591 times for 858 patients. In total Marko R Gudziak billed 13,101 services in 119 codes, and Medicare paid $422K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-07-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 81003 Clinical Chemistry | Office | 1,591 | 858 | $2.17 | $3,459 |
| 99214 Office E&M - Established | Office | 1,431 | 822 | $95.12 | $136K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,226 | 774 | $12.57 | $15K |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 1,150 | 12 | $2.27 | $2,610 |
| 80048 Clinical Chemistry | Office | 553 | 408 | $8.26 | $4,569 |
| 84153 Clinical Chemistry | Office | 454 | 335 | $17.95 | $8,148 |
| 51798 Ultrasound - Nonspecific | Office | 437 | 324 | $8.65 | $3,780 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 384 | 69 | $50.74 | $19K |
| 76770 Ultrasound - Abdomen and Pelvis | Office | 317 | 171 | $34.50 | $11K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 182 | 65 | $38.85 | $7,071 |
| 52000 Cystourethroscopy | Office | 154 | 136 | $177.86 | $27K |
| 51728 Other Organ Systems | Office | 137 | 133 | $257.92 | $35K |
| 84154 Clinical Chemistry | Office | 132 | 107 | $18.02 | $2,379 |
| 99204 Office E&M - New | Office | 120 | 120 | $121.10 | $15K |
| 99232 Hospital E&M - Subsequent | Facility | 111 | 75 | $65.03 | $7,218 |
By year: 2022 $460K for 12,856 services; 2023 $411K for 11,149 services; 2024 $422K for 13,101 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 1,591 | 858 | $2.17 | $3,459 |
| 80048 Clinical Chemistry | 553 | 408 | $8.26 | $4,569 |
| 84153 Clinical Chemistry | 454 | 335 | $17.95 | $8,148 |
| 84154 Clinical Chemistry | 132 | 107 | $18.02 | $2,379 |
| 80076 Clinical Chemistry | 37 | 22 | $8.01 | $296 |
| 84403 Clinical Chemistry | 35 | 20 | $25.29 | $885 |
| 85025 Blood Count | 28 | 17 | $7.61 | $213 |
| 84100 Clinical Chemistry | 25 | 11 | $4.65 | $116 |
| 83735 Clinical Chemistry | 25 | 11 | $6.57 | $164 |
Medicare prescription drug claims, 2024
In 2024, the drug Marko R Gudziak prescribed most often to Medicare patients was Tamsulosin Hcl, with 1,616 prescriptions and refills. In total Marko R Gudziak wrote 6,032 Medicare prescriptions that cost $860K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 1,616 | 4,533 | 522 | $33K |
| Finasteride Generic | 1,440 | 4,015 | 438 | $30K |
| Methenamine Hippurate Generic | 467 | 1,245 | 160 | $46K |
| Alfuzosin Hcl Er Alfuzosin Hcl | 289 | 733 | 105 | $8,565 |
| Myrbetriq Mirabegron | 273 | 589 | 90 | $252K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 182 | 487 | 56 | $9,616 |
| Solifenacin Succinate Generic | 153 | 370 | 57 | $4,995 |
| Tolterodine Tartrate Er Tolterodine Tartrate | 153 | 394 | 53 | $14K |
| Nitrofurantoin Nitrofurantoin Macrocrystal | 142 | 359 | 64 | $6,238 |
| Tadalafil Generic | 120 | 216 | 29 | $2,753 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 118 | 169 | 84 | $659 |
| Cephalexin Generic | 90 | 188 | 57 | $2,267 |
| Trospium Chloride Generic | 83 | 192 | 33 | $7,229 |
| Oxybutynin Chloride Generic | 81 | 215 | 28 | $2,575 |
| Doxazosin Mesylate Generic | 65 | 181 | 21 | $1,053 |
Brand drugs: - claims; generic drugs: 5,625 claims; opioid claims: 12.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marko R Gudziak $1,014 ($1,014 in general payments such as food, travel and fees) from 13 companies. The largest payer was Abbvie Inc. with $264.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 13 | $264 |
| Sumitomo Pharma America, Inc. 4506.T | 6 | $131 |
| Boston Scientific Corporation BSX | 2 | $108 |
| Olympus America Inc. | 4 | $89.88 |
| Urogen Pharma, Inc. URGN | 3 | $82.75 |
| Endo USA, Inc. | 3 | $61.32 |
| Medtronic, Inc. MDT | 3 | $58.36 |
| Dendreon Pharmaceuticals LLC | 2 | $55.44 |
| Verity Pharmaceuticals Inc. | 2 | $48.75 |
| Antares Pharma, Inc. | 2 | $35.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.